Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Cerebrospinal Fluid Neurofilament Light Concentration Predicts Brain Atrophy And Cognition In Alzheimer's Disease, Kunal Dhiman, Veer Bala Gupta, Victor L. Villemagne, Dhamidhu Eratne, Petra L. Graham, Christopher Fowler, Pierrick Bourgeat, Qiao-Xin Li, Steven Collins, Ashley I. Bush, Christopher C. Rowe, Colin L. Masters, David Ames, Eugene Hone, Kaj Blennow, Henrik Zetterberg, Ralph N. Martins
Cerebrospinal Fluid Neurofilament Light Concentration Predicts Brain Atrophy And Cognition In Alzheimer's Disease, Kunal Dhiman, Veer Bala Gupta, Victor L. Villemagne, Dhamidhu Eratne, Petra L. Graham, Christopher Fowler, Pierrick Bourgeat, Qiao-Xin Li, Steven Collins, Ashley I. Bush, Christopher C. Rowe, Colin L. Masters, David Ames, Eugene Hone, Kaj Blennow, Henrik Zetterberg, Ralph N. Martins
Research outputs 2014 to 2021
Introduction
This study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation.
Methods
CSF NfL concentration was measured in 221 participants from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL).
Results
CSF NfL levels as well as NfL/amyloid β (Aβ42) were significantly elevated in AD compared to healthy controls (HC; P < .001), and in mild cognitive impairment (MCI) compared to HC (P = .008 NfL; P< .001 NfL/Aβ42). CSF NfL and NfL/Aβ42 differentiated AD from HC with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.84 and 0.90, respectively. CSF NfL and NfL/Aβ42 predicted cortical amyloid load, brain atrophy, and cognition.
Discussion
CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology.
Predictors Of Noncompliance To Antihypertensive Therapy Among Hypertensive Patients Ghana: Application Of Health Belief Model, Yaa Obirikorang, Christian Obirikorang, Emmanuel Acheampong, Enoch Odame Anto, Daniel Gyamfi, Selorm Philip Segbefia, Michael Opoku Boateng, Dari Pascal Dapilla, Peter Kojo Brenya, Bright Amankwaa, Evans Asamoah Adu, Emmanuel Nsenbah Batu, Adjei Gyimah Akwasi, Beatrice Amoah
Predictors Of Noncompliance To Antihypertensive Therapy Among Hypertensive Patients Ghana: Application Of Health Belief Model, Yaa Obirikorang, Christian Obirikorang, Emmanuel Acheampong, Enoch Odame Anto, Daniel Gyamfi, Selorm Philip Segbefia, Michael Opoku Boateng, Dari Pascal Dapilla, Peter Kojo Brenya, Bright Amankwaa, Evans Asamoah Adu, Emmanuel Nsenbah Batu, Adjei Gyimah Akwasi, Beatrice Amoah
Research outputs 2014 to 2021
This study determined noncompliance to antihypertensive therapy (AHT) and its associated factors in a Ghanaian population by using the health belief model (HBM). This descriptive cross-sectional study conducted at Kintampo Municipality in Ghana recruited a total of 678 hypertensive patients. The questionnaire constituted information regarding sociodemographics, a five-Likert type HBM questionnaire, and lifestyle-related factors. The rate of noncompliance to AHT in this study was 58.6%. The mean age (SD) of the participants was 43.5 (±5.2) years and median duration of hypertension was 2 years. Overall, the five HBM constructs explained 31.7% of the variance in noncompliance to AHT with a …